Literature DB >> 28449432

Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty?

Dario Buccheri1,2, Giuseppe Caramanno1, Salvatore Geraci1, Bernardo Cortese2.   

Abstract

Year:  2017        PMID： 28449432      PMCID： PMC5394001          DOI： 10.21037/jtd.2017.03.05

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Current know how on the absorb BVS technology: an experts' survey.

Authors:  Bernardo Cortese; Marco Valgimigli
Journal:  Int J Cardiol       Date:  2014-11-25       Impact factor: 4.164

3.  Current-era biovascular scaffolds seen by experts: An experience-based survey.

Authors:  Dario Buccheri; Marco Valgimigli; Bernardo Cortese
Journal:  Int J Cardiol       Date:  2015-04-01       Impact factor: 4.164

4.  The Contemporary Pulse of Bioresorbable-Scaffold Thrombosis Among Expert Operators.

Authors:  Bernardo Cortese; Dario Buccheri; Giulio G Stefanini; Roxana Mehran
Journal:  J Am Coll Cardiol       Date:  2016-06-21       Impact factor: 24.094

5.  Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.

Authors:  Robert W Yeh; Dean J Kereiakes; Philippe Gabriel Steg; Stephan Windecker; Michael J Rinaldi; Anthony H Gershlick; Donald E Cutlip; David J Cohen; Jean-Francois Tanguay; Alice Jacobs; Stephen D Wiviott; Joseph M Massaro; Adrian C Iancu; Laura Mauri
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

6.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.

Authors:  Davide Capodanno; Tommaso Gori; Holger Nef; Azeem Latib; Julinda Mehilli; Maciej Lesiak; Giuseppe Caramanno; Christoph Naber; Carlo Di Mario; Antonio Colombo; Piera Capranzano; Jens Wiebe; Aleksander Araszkiewicz; Salvatore Geraci; Stelios Pyxaras; Alessio Mattesini; Toru Naganuma; Thomas Münzel; Corrado Tamburino
Journal:  EuroIntervention       Date:  2015-02       Impact factor: 6.534

7.  Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.

Authors:  Philip Urban; Alex Abizaid; Bernard Chevalier; Samantha Greene; Ian Meredith; Marie-Claude Morice; Stuart Pocock
Journal:  Am Heart J       Date:  2013-02-19       Impact factor: 4.749

8.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.

Authors:  Patrick W Serruys; Bernard Chevalier; Yohei Sotomi; Angel Cequier; Didier Carrié; Jan J Piek; Ad J Van Boven; Marcello Dominici; Dariusz Dudek; Dougal McClean; Steffen Helqvist; Michael Haude; Sebastian Reith; Manuel de Sousa Almeida; Gianluca Campo; Andrés Iñiguez; Manel Sabaté; Stephan Windecker; Yoshinobu Onuma
Journal:  Lancet       Date:  2016-10-30       Impact factor: 79.321

9.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Authors:  Robert W Yeh; Eric A Secemsky; Dean J Kereiakes; Sharon-Lise T Normand; Anthony H Gershlick; David J Cohen; John A Spertus; Philippe Gabriel Steg; Donald E Cutlip; Michael J Rinaldi; Edoardo Camenzind; William Wijns; Patricia K Apruzzese; Yang Song; Joseph M Massaro; Laura Mauri
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

Review 10.  Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.

Authors:  Tullio Palmerini; Diego Della Riva; Umberto Benedetto; Letizia Bacchi Reggiani; Fausto Feres; Alexandre Abizaid; Martine Gilard; Marie-Claude Morice; Marco Valgimigli; Myeong-Ki Hong; Byeong-Keuk Kim; Yangsoo Jang; Hyo-Soo Kim; Kyung Woo Park; Antonio Colombo; Alaide Chieffo; Diego Sangiorgi; Giuseppe Biondi-Zoccai; Philippe Généreux; Gianni D Angelini; Maria Pufulete; Jonathon White; Deepak L Bhatt; Gregg W Stone
Journal:  Eur Heart J       Date:  2017-04-07       Impact factor: 29.983
View more
  1 in total

Review 1.  Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future?

Authors:  Ioannis Merinopoulos; Tharusha Gunawardena; Upul Wickramarachchi; Alisdair Ryding; Simon Eccleshall; Vassilios S Vassiliou
Journal:  Curr Cardiol Rev       Date:  2018-03-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.